WASHINGTON — Two prominent Democratic lawmakers are requesting that the Federal Trade Commission investigate whether price hikes for two blockbuster blood thinners were illegally coordinated by Janssen and Bristol Myers Squibb.
Sen. Amy Klobuchar (D-Minn.), the chair of the Senate Judiciary Committee’s subcommittee on antitrust enforcement, and Rep. Katie Porter (D-Calif.), a rising star in the Democratic Party and a member of the House’s oversight panel, wrote to the FTC on Monday regarding what they called “parallel” price hikes on Xarelto and Eliquis, drugs that patients take to prevent heart attacks, strokes, and blood clots.
“We are principally concerned that the prices for these products, which are close substitutes for each other, have been raised in lockstep in a manner that seems coordinated to maintain pricing parity,” the lawmakers wrote.
Create a display name to comment
This name will appear with your comment